

## Claims

1. A compound of Formula (I):



(I)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

Z is selected from -CHO, -CN, -$CH_2CN$, -C(=O)-$CH=CH_2$, -NH-C(=O)-$CH=CH_2$, -$CH_2$-C(=O)-$CH=CH_2$, -C(=O)$CH_2OH$, , -$CH(OH)SO_3^-$ (and an associated cation, such as $Na^+$), -$CO_2$-$C_{1-3}$alkyl, -$CH_2OH$, -C(=O)OH, -$CH(OCH_3)_2$, and -C(=O)-$C_{1-3}$haloalkyl;

L is selected from a bond, -$(CR_2)_{1-2}$-, -$(CR_2)_{0-2}$-NR-, -NR-$(CR_2)_{0-2}$, -$(CR_2)_{0-2}$-O-, -O-$(CR_2)_{0-2}$, -$(CR_2)_{0-2}$-C(=O)-NR-, -NR-C(=O)-$(CR_2)_{0-2}$-, -NR-C(=O)-$CHR^2$-NR-C(=O)-$(CR_2)_{0-2}$-, -NR-C(=O)-$CHR^2$-NR-C(=O)-O-$(CR_2)_{0-2}$-, -$(CR_2)_{0-2}$-C(=O)-NR-$CHR^2$-C(=O)-NR-, -$(CR_2)_{0-2}$-O-C(=O)-NR-$CHR^2$-C(=O)-NR-, -NR-C(=O)-O-$(CR_2)_{0-2}$-, and -$(CR_2)_{0-2}$-O-C(=O)-NR-;

$R^1$ is selected from -$CF_3$, -$CHF_2$, -$CH_2F$, phenyl, naphthyl, and 5-10 membered heteroaryl containing one or two heteroatoms selected from N, O and S as ring members, and wherein each phenyl, naphthyl, and 5-10 membered heteroaryl is optionally substituted with one to three groups independently selected from halo, CN, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy;

each $R^2$ is selected from $C_{1-6}$ alkyl, 3-7 membered cycloalkyl, $C_{1-3}$ alkyl-(3-7 membered cycloalkyl), and (3-7 membered cycloalkyl)-$C_{1-3}$ alkyl, each of which is optionally substituted with up to three groups selectedfrom halo, CN, $C_{1-3}$ alkyl, $C_{1-6}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy;

$R^3$ is H or $C_{1-4}$ alkyl;

Each R* is independently selected from $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, CN,


halo, and -OH;

m is an integer from 0 to 2;

n is an integer from 0 to 4; and

each R is independently selected from H and $C_{1-4}$ alkyl.


2. The compound of claim 1, which is a compound of Formula (IA)



(IA)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


3. The compound of claim 1, which is a compound of Formula (IB):



(IB)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


4. The compound of claim 1, which is a compound of Formula (IC):



(IC)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


5. The compound of claim 1, which is a compound of Formula (IC1):



(IC1)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


6. The compound of claim 1, which is a compound of Formula (IC1A):



(IC1A)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

7. The compound of claim 1, which is a compound of Formula (ID):




(ID)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer,


a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

8. The compound of claim 1, which is a compound of Formula (ID1):



or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

9. The compound of claim 1, which is a compound of Formula (IE):




(IE),

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

each $R^5$ is independently selected from hydrogen, halo, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy; and

p is an integer from 0 to 4.

10. The compound of claim 1, which is a compound of Formula (IF):




(IF),

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

$R^5$ is selected from hydrogen, halo, $C_{1-3}$ alkyl, and $C_{1-3}$ alkoxy.


11. The compound of claim 1, which is a compound of Formula (IG):



(IG)


or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

12. The compound of claim 1, which is a compound of Formula (IG1):



(IG1) or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

13. The compound of claim 1, which is a compound of Formula (IG2):



(IG2)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

14. The compound of any one of claims 1-13, wherein each $R^2$ is independently $C_{1-4}$ alkyl, 3-7 membered cycloalkyl, $C_{1-2}$ alkyl-( $C_{3-6}$ cycloalkyl) or ($C_{3-6}$ cycloalkyl)$C_{1-2}$alkyl optionally substituted with $C_{1-6}$ alkoxy.

15. The compound of claim 14, wherein each $R^2$ is independently methyl, ethyl, propyl, isopropyl, t-butyl, isobutyl, isopropylmethyl, 1-methyl-t-butoxyethyl, cyclopropyl, cyclohexyl, cyclopropylmethyl, or cyclohexylmethyl.

16. The compound of claim 14, wherein each $R^2$ is independently t-butyl, isopropylmethyl, cyclohexylmethyl or 1-methyl-t-butoxyethyl.

17. The compound of any one of claims 1-4, 7, 8, or 14-16, wherein $R^1$ is phenyl, naphthyl, or indolyl,each of which is optionally substituted with one or two groups selected from halo, CN, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-6}$ haloalkoxy.

18. The compound of claim 17, wherein $R^1$ is phenyl or indolyl each of which is optionally substituted with one group selected from halo, $C_{1-3}$ alkyl, and $C_{1-3}$ alkoxy.

19. The compound of claim 17, wherein $R^1$ is $-CF_3$ or $-CHF_2$.

20. The compound of claim 17, wherein $R^1$ is $-CF_3$, $-CHF_2$, phenyl or indolyl, and wherein phenyl and indolyl are optionally substituted with one group selected from halo, $C_{1-3}$ alkyl, and $C_{1-3}$ alkoxy.

21. The compound of claim 17, wherein $R^1$ is $-CF_3$, $-CHF_2$, phenyl or indolyl, and

wherein phenyl and indolyl are optionally substituted with one group selected from fluoro, methyl and methoxy.

22. The compound of any one of claims 1-4, 7-10, or 14-21, wherein n is 1, 2 or 3.

23. The compound of claim 22, wherein n is 1.

24. The compound of claim 22, wherein n is 2.

25. The compound of claim 22, wherein n is 3.

26. The compound of any one of claims 9-12 or 14-25, wherein m is 0.

27. The compound of any one of claims 1-4, 7, 9, or 14-26, wherein each $R^5$ is independently hydrogen, halo, $C_{1-3}$ alkyl, or $C_{1-3}$ alkoxy.

28. The compound of claim 27, wherein each $R^5$ is independently hydrogen, fluoro, methyl, or methoxy.


29. The compound of any one of claims 1-28, wherein Z is -CN, $-CO_2CH_3$, $-CH_2OH$, -C(=O)OH, $-NHC(=O)CH=CH_2$, $-C(=O)CH=CH_2$, $-C(=O)CH_2OH$, $-CH(OCH_3)_2$, -CHO, $-CH(OH)SO_3^-$ (and an associated cation, such as $Na^+$), or -C(=O)-CH2X, and wherein X is F, Cl, Br, or I.


30. The compound of claim 29, wherein Z is $-CH(OH)SO_3^-$ (and an associated cation, such as $Na^+$).


31. The compound of claim 1, wherein L is -NHC(=O)-, -C(=O)NH-, $-NHC(=O)-CHR^2-NHC(=O)-$, or $-C(=O)NH-CHR^2-C(=O)NH-$.


32. The compound of claim 31, wherein L is -NHC(=O)- or -C(=O)NH-.


33. A compound selected from:





















































































































































































































and

;


and tautomers, mixtures of two or more tautomers, and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof.


34. A compound selected from:












































and

;

and tautomers, mixtures of two or more tautomers, and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof.


35. A compound of Formula (II):



(II)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

Ring A is a 5-9 atom cycloalkyl that is optionally substituted with up to three groups selected from $C_{1-3}$ alkyl, $C_{1-6}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy;

Z is selected from -CHO, -$CH_2$CN, -C(=O)-CH=$CH_2$, -$CH_2$-C(=O)-CH=$CH_2$, -C(=O)-$C_{1-3}$ haloalkyl, and -NH-C(=O)-CH=$CH_2$, -C(=O)$CH_2$OH, , and -CH(OH)$SO_3^-$ (and an associated cation, such as $Na^+$);

or Z can be -CN provided $R^2$ is not t-butyl when n is 1;

$R^1$ is H , 3-7 membered cycloalkyl, $C_{1-4}$alkoxy, or $C_{1-4}$ alkyl, wherein the 3-7 membered cycloalkyl, $C_{1-4}$alkoxy and $C_{1-4}$ alkyl are optionally substituted with one to three groups independentlyselected from halo, CN, $C_{3-6}$ cycloalkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy; or $R^1$ is 5-10 membered heteroaryl containing one or two heteroatoms selected from N, O and S as ring members, and wherein the 5-10 membered heteroaryl is optionally substituted with one to three groups independently selected from halo, CN, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy;

$R^2$ is selected from $C_{1-6}$ alkyl, 3-7 membered cycloalkyl, $C_{1-3}$ alkyl-(3-7 membered cycloalkyl), and (3-7 membered cycloalkyl)- $C_{1-3}$ alkyl, each of which is optionally substituted with up to three groups selected from halo, CN, $C_{1-3}$ alkyl, $C_{1-6}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy;


$R^3$ is H or $C_{1-4}$ alkyl;

each R* is independently selected from $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, CN, halo, and -OH;

m is an integer from 0 to 2; and

n is an integer from 0 to 4.


36. The compound of claim 35, which is a compound of Formula (IIA):



(IIA)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


37. The compound of claim 35, which is a compound of Formula (IIA1):



(IIA1)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


38. The compound of claim 35, which is a compound of Formula (IIB):



(IIB)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


39. The compound of claim 35, which is a compound of Formula (IIB1):



(IIB1)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


40. The compound of claim 35, which is a compound of Formula (IIB1A):



(IIB1A)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


41. The compound of claim 35, which is a compound of Formula (IIB2):



(IIB2)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


42. The compound of claim 35, which is a compound of Formula (IIB2A):



(IIB2A)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


43. The compound of claim 35, which is a compound of Formula (IIB3):



(IIB3)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


44. The compound of claim 35, which is a compound of Formula (IIB4):



(IIB4)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


45. The compound of claim 35, which is a compound of Formula (IIB5):



(IIB5)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

46. The compound of claim 35, which is a compound of Formula (IIC):




(IIC)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

each $R^5$ is independently selected from hydrogen, halo, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy; and

p is an integer from 0 to 4.

47. The compound of claim 35, which is a compound of Formula (IID):




(IID)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

$R^5$ is selected from hydrogen, halo, $C_{1\text{-}3}$ alkyl, and $C_{1\text{-}3}$ alkoxy.


48. The compound of claim 35, which is a compound of Formula (IID1):



(IID1)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


49. The compound of claim 35, which is a compound of Formula (IID1A):



(IID1A)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


50. The compound of claim 35, which is a compound of Formula (IID2):



(IID2)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

51. The compound of claim 35, which is a compound of Formula (IID2A):



(IID2A)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

52. The compound of any one of claims 46-48 or 50, wherein each $R^5$ is independently hydrogen, halo, $C_{1-3}$ alkyl, or $C_{1-3}$ alkoxy.

53. The compound of claim 52, wherein each $R^5$ is independently hydrogen, fluoro, methyl, or methoxy.

54. The compound of any one of claims 35-53, wherein $R^2$ is selected from ethyl, isopropyl, isobutyl, t-butyl, isopropylmethyl, cyclopropyl, cyclohexyl, and cyclobutyl.

55. The compound of claim 54, wherein $R^2$ is t-butyl, isopropylmethyl, or cyclopropyl.

56. The compound of any one of claims 35-38 or 52-55, wherein $R^1$ is trifluoromethyl, difluoromethyl, cyclopropyl, t-butyl, t-butoxy; or indolyl optionally substituted with one or two groups selected from fluoro, methyl and methoxy.

57. The compound of any one of claims 35-37 or 46, wherein n is 1 or 2.


58. The compound of any one of claims 35-37 or 46, wherein m is 0.


59. The compound of any one of claims 25-58, wherein Z is -CN, $-CO_2CH_3$, $-CH_2CN$, $NHC(=O)CH=CH_2$, $-C(=O)CH_2OH$, -CHO, $-CH(OH)SO_3^-$ (and an associated cation, such as $Na^+$), or $-C(=O)-CH_2X$, and wherein X is F, Cl, Br, or I.


60. The compound of claim 59, wherein Z is -CN.


61. The compound of claim 59, wherein Z is $-CH(OH)SO_3^-$ (and an associated cation, such as $Na^+$) or $-C(=O)-CH_2X$, and wherein X is F, Cl, Br, or I.


62. A compound, selected from:































































































































































































































































































































































































































































































































































































































































































































and ;


and tautomers, mixtures of two or more tautomers, and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof.


63. A compound selected from:










































and ;

and tautomers, mixtures of two or more tautomers, and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof.

64. A compound of Formula (III):




(III)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

Ring A is a 5-9 atom cycloalkyl that is optionally substituted with up to three groups

selected from $C_{1-3}$ alkyl, $C_{1-6}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy;

Z is selected from -CHO, -CN, $-CH_2CN$, $-C(=O)-CH=CH_2$, $-CH_2-C(=O)-CH=CH_2$, $-C(=O)-C_{1-3}$ haloalkyl, and $-NH-C(=O)-CH=CH_2$, $-C(=O)CH_2OH$, , and $-CH(OH)SO_3^-$ (and an associated cation, such as $Na^+$);

$R^1$ is H, 3-7 membered cycloalkyl, $C_{1-4}$alkoxy, $C_{1-4}$ alkyl optionally substituted with one to three groups independentlyselected from halo, CN, $C_{3-6}$ cycloalkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy, or 5-10 membered heteroaryl containing one or two heteroatoms selected from N, O and S as ring members, and wherein the 5-10 membered heteroaryl is optionally substituted with one to three groups independently selected from halo, CN, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy;


$R^2$ is selected from $C_{1-6}$ alkyl, 3-7 membered cycloalkyl, $C_{1-3}$ alkyl-(3-7 membered cycloalkyl), and (3-7 membered cycloalkyl)- $C_{1-3}$ alkyl, each of which is optionally substituted with up to three groups selected from halo, CN,$C_{1-3}$ alkyl, $C_{1-6}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy;

$R^3$ is H or $C_{1-4}$ alkyl; and

$R^6$ is hydrogen, halo, $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, $C_{1-3}$ haloalkyl, or $C_{1-3}$ haloalkoxy

.


65. The compound of claim 64, which is a compound of Formula (IIIA):



(IIIA)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


66. The compound of claim 64, which is a compound of Formula (IIIB):



(IIIB)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

67. The compound of claim 64, which is a compound of Formula (IIIC):




(IIIC)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

each $R^5$ is independently selected from hydrogen, halo, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, $C_{1-3}$ haloalkyl, and $C_{1-3}$ haloalkoxy; and

p is an integer from 0 to 4.

68. The compound of claim 64, which is a compound of Formula (IIID):




(IIID)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein:

$R^5$ is selected from hydrogen, halo, $C_{1\text{-}3}$ alkyl, and $C_{1\text{-}3}$ alkoxy.


69. The compound of claim 64, which is a compound of Formula (IIID1):



(IIID1)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


70. The compound of claim 64, which is a compound of Formula (IIID1A):



(IIID1A)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


71. The compound of claim 64, which is a compound of Formula (IIID1B):



(IIID1B)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


72. The compound of claim 64, which is a compound of Formula (IIID1C):



(IIID1C)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


73. The compound of claim 64, which is a compound of Formula (IIIE):



(IIIE)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


74. The compound of claim 64, which is a compound of Formula (IIIE1):



(IIIE1)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.


75. The compound of claim 64, which is a compound of Formula (IIIE2):



(IIIE2)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

76. The compound of claim 64, which is a compound of Formula (IIIE3):



(IIIE3)

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

77. The compound of claim 67 or 68, wherein each $R^5$ is independently hydrogen, halo, $C_{1-3}$ alkyl, or $C_{1-3}$ alkoxy.

78. The compound of claim 77, wherein each $R^5$ is independently hydrogen, fluoro, methyl, or methoxy.

79. The compound of any one of claims 64-78, wherein $R^2$ is selected from ethyl, isopropyl, isobutyl, t-butyl, isopropylmethyl, cyclopropyl, cyclohexyl, and cyclobutyl.

80. The compound of claim 79, wherein $R^2$ is t-butyl, isopropylmethyl, or cyclopropyl.

81. The compound of any one of claims 64-66 and 77-80, wherein $R^1$ is trifluoromethyl, difluoromethyl, cyclopropyl, isopropyl, t-butyl, isopropylmethyl, t-butoxy; or indolyl optionally substituted with one or two groups selected from fluoro, methyl and methoxy.

82. The compound of claim 81, wherein $R^1$ is trifluoromethyl or indolyl optionally substituted with one or two groups selected from fluoro, methyl and methoxy.


83. The compound of any one of claims 64-69, 73, and 77-82, wherein $R^6$ is $C_{1-6}$ alkyl.


84. The compound of claim 83, wherein $R^6$ is methyl, isopropyl, or t-butyl.


85. The compound of any one of claims 64-84 and 77-84, wherein Z is $-CO_2CH_3$, -CHO, -CN, $-C(=O)-C_{1-3}$ haloalkyl, $-NH-C(=O)-CH=CH_2$, or $-CH(OH)SO_3^-$ (and an associated cation, such as $Na^+$).


86. The compound of claim 85, wherein Z is $-CH(OH)SO_3^-$ (and an associated cation, such as $Na^+$) or $-C(=O)-CH_2X$, where X is F, Cl, Br, or I.


87. A compound, selected from:




























































































































































































































































































































































and  ;


and tautomers, mixtures of two or more tautomers, and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof.


88. A compound selected from:

























































and  ;

and tautomers, mixtures of two or more tautomers, and isotopic variants thereof; and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof.

89. A pharmaceutical composition comprising a compound of any one of claims 1-88 and atleast one pharmaceutically acceptable excipient.

90. The pharmaceutical composition of claim 89, further comprising a second therapeutic agent.

91. A compound according to any one of claims 1-88 or the pharmaceutical composition of claim 89 or 90 for use in therapy.

92. The compound for use according to claim 91, wherein therapy is for treatment of a viral infection.

93. Use of a compound according to any one of claims 1-88 or the pharmaceutical composition of claim 89 or 90 for the manufacture of a medicament for treating a viral infection.

94. The compound for use according to claim 92, or the use of claim 93, wherein the viral infection is a coronavirus infection, optionally wherein the coronavirus infection is a SARS-CoV-2 infection.